A. Walsh

发表

Acute Severe Ulcerative Colitis: Evidence Based Consensus Statements

I. Lawrance, G. Radford-Smith, S. Connor, 2017 .

Comparing disease activity indices in ulcerative colitis.

G. Collins, S. Travis, D. Burger, 2014, Journal of Crohn's & colitis.

Plasma Nuclear Magnetic Resonance Metabolomics Discriminates Between High and Low Endoscopic Activity and Predicts Progression in a Prospective Cohort of Patients With Ulcerative Colitis

S. Travis, A. Simmons, D. Anthony, 2018, Journal of Crohn's & colitis.

Beyond Histological Remission: Intramucosal Calprotectin as a Potential Predictor of Outcomes in Ulcerative Colitis

S. Travis, R. Bryant, O. Brain, 2016, Journal of Crohn's & colitis.

Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity.

S. Travis, A. Walsh, R. Palmer, 2014, Gastrointestinal endoscopy clinics of North America.

The pattern and outcome of acute severe colitis.

Fraser Cummings, B. Warren, S. Travis, 2010, Journal of Crohn's & Colitis.

Real-time data monitoring for ulcerative colitis: patient perception and qualitative analysis

G. Collins, G. Goodwin, J. Geddes, 2019, Intestinal research.

The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis.

D. Hewett, G. Anderson, L. Powell, 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

S. Travis, S. Goodday, Stephen H. Friend, 2021, European journal of gastroenterology & hepatology.

Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes.

Steven J Brown, B. Bibby, M. Kamm, 2019, Inflammatory Bowel Diseases.

Using item response theory (IRT) to improve the efficiency of the Simple Clinical Colitis Activity Index (SCCAI) for patients with ulcerative colitis

M. South, S. Travis, S. Bauermeister, 2020, BMC Gastroenterology.

Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.

Steven J Brown, N. Uldbjerg, B. Bibby, 2016, Gastroenterology.

Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study

M. Samaan, P. Irving, A. Walsh, 2022, Frontline Gastroenterology.

ECCO Position Paper: Harmonisation of the approach to Ulcerative Colitis Histopathology.

L. Peyrin-Biroulet, S. Danese, V. Villanacci, 2020, Journal of Crohn's & colitis.

Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus

S. Travis, J. Mary, L. Peyrin-Biroulet, 2017, Alimentary pharmacology & therapeutics.

Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic

J. Satsangi, P. Klenerman, R. Sadler, 2021, Gut.

Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational study.

W. Selby, J. Andrews, P. Bampton, 2014, Journal of Crohn's & colitis.

Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response

J. Satsangi, S. Travis, O. Brain, 2022, Gut.

Crohn’s Colitis Care (CCCare): bespoke cloud-based clinical management software for inflammatory bowel disease

J. Andrews, G. Radford-Smith, A. Sechi, 2020, Scandinavian journal of gastroenterology.

Real-World Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multi-Centre UK Experience.

J. Satsangi, T. Ahmad, N. Kennedy, 2020, Journal of Crohn's & colitis.

Dose tailoring of anti‐tumour necrosis factor‐alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response

J. Andrews, I. Lawrance, A. Sechi, 2015, Internal medicine journal.

Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease.

W. Selby, S. Travis, I. Lawrance, 2013, Journal of Crohn's & colitis.

The need for better preventative strategies for inflammatory bowel disease patients at risk of herpes zoster virus

J. Andrews, S. Connor, M. Sparrow, 2017, Internal medicine journal.

Fusion of colour contrasted images for early detection of oesophageal squamous cell dysplasia from endoscopic videos in real time

J. Satsangi, P. Klenerman, F. Powrie, 2022, Inf. Fusion.

Patient-reported Outcomes: the ICHOM Standard Set for Inflammatory Bowel Disease in Real-life Practice Helps Quantify Deficits in Current Care

J. Satsangi, J. Geddes, K. Bodger, 2022, Journal of Crohn's & colitis.

Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis.

J. Clemente, J. Faith, M. Wilkins, 2019, Gastroenterology.

HLA-DQA1–HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants

M. Tremelling, M. Parkes, C. Lees, 2014, Nature Genetics.

Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial

M. Kamm, T. Borody, S. Connor, 2017, The Lancet.

Gastroenterologist perceptions of faecal microbiota transplantation.

M. Kamm, T. Borody, S. Connor, 2015, World journal of gastroenterology.

Performance of risk prediction for inflammatory bowel disease based on genotyping platform and genomic risk score method

Sang Hong Lee, Peter M Visscher, Naomi R Wray, 2017, BMC Medical Genetics.

A dynamic CD2-rich compartment at the outer edge of the immunological synapse boosts and integrates signals

J. Satsangi, P. Klenerman, M. Meyer-Hermann, 2020, Nature Immunology.

Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up

B. Warren, S. Travis, R. Bryant, 2015, Gut.

Optimising Early Management of Acute Severe Ulcerative Colitis in the Biologics Era: Admission Model for Intensification of Therapy in Acute Severe Colitis (ADMIT-ASC)

J. Satsangi, S. Travis, O. Brain, 2021, medRxiv.

Donor Recruitment for Fecal Microbiota Transplantation

Sarah Finlayson, M. Kamm, T. Borody, 2015, Inflammatory bowel diseases.

An Extremes of Phenotype Approach Confirms Significant Genetic Heterogeneity in Patients with Ulcerative Colitis

G. Montgomery, J. Andrews, P. Bampton, 2021, bioRxiv.

Compassionate access anti‐tumour necrosis factor‐α therapy for ulcerative colitis in Australia: the benefits to patients

P. Bampton, A. Sechi, S. Connor, 2015, Internal medicine journal.

Surgical outcomes in steroid refractory acute severe ulcerative colitis: the impact of rescue therapy

G. Radford-Smith, A. Croft, G. Radford-Smith, 2013, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

Outcomes of salvage therapy for steroid‐refractory acute severe ulcerative colitis: ciclosporin vs. infliximab

G. Radford-Smith, A. Croft, J. Doecke, 2013, Alimentary pharmacology & therapeutics.

W1205 How Variable Is the Mayo Score Between Observers and Might This Affect Trial Recruitment or Outcome

D. Altman, S. Travis, M. Rolinski, 2009 .

Current best practice for disease activity assessment in IBD

S. Travis, R. Bryant, A. Walsh, 2016, Nature Reviews Gastroenterology &Hepatology.

What's app? Electronic health technology in inflammatory bowel disease

S. Travis, A. Walsh, 2018, Intestinal research.

Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis—a Prospective Analysis

G. Collins, G. Goodwin, J. Geddes, 2018, Journal of Crohn's & colitis.

Obstacles to Donor Recruitment for Faecal Microbiota Transplantation: Experiences From the FOCUS Study: 650

M. Kamm, T. Borody, N. Kaakoush, 2014 .